By Fineline Cube Zhuhai Trinomab Pharmaceutical Co., Ltd. (SHA: 688806) announced that its Category 1 pediatric innovative drug, Retavibart Injection (trade name: Xinduotuo, development code: TNM001), has been officially approved for marketing in China through the National Medical Products Administration’s (NMPA) priority review and approval process. The long-acting monoclonal antibody is indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract infections in neonates and infants entering or born during their first RSV season — and stands as the world’s first RSV monoclonal antibody with up to nine months of clinical protection data from a single dose.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | Marketing approval via priority review and approval process |
| Product | Retavibart Injection (Xinduotuo; TNM001), Category 1 pediatric innovative drug |
| Indication | Prevention of RSV lower respiratory tract infections in neonates and infants about to enter or born during their first RSV season |
| Date | 04 Sept 2026 |
| Developer | Zhuhai Trinomab Biopharmaceutical Co., Ltd. |
Drug Profile & Mechanism of Action
- Molecule: Retavibart, a recombinant long-acting, fully human monoclonal antibody against RSV, independently developed by Trinomab
- Target: A conserved epitope on the pre-fusion (Pre-F) conformation of the RSV fusion protein
- Mechanism: Mediates RSV neutralization and prevents viral fusion with host cells, thereby blocking viral entry and exerting passive immunoprophylaxis
- Durability: The world’s first RSV monoclonal antibody providing up to nine months of clinical protection data with a single dose
- Regulatory Pathway: Approved via NMPA priority review, reflecting the significant unmet need in infant RSV prevention
Clinical Evidence – Pivotal Phase 3 Trial (TNM001-301)
| Endpoint | 150 Days Post-Dose | 270 Days Post-Dose |
|---|---|---|
| Efficacy against medically attended RSV LRTI | 71.3% | 69.9% |
| Efficacy against RSV LRTI leading to hospitalization | 71.7% | 69.8% |
| Efficacy against severe RSV LRTI (medically attended) | 93.9% | 90.2% |
| Efficacy against severe RSV LRTI (leading to hospitalization) | 90.1% | 83.5% |
The primary endpoints of the pivotal TNM001-301 Phase 3 study showed that within 150 days post-administration, Retavibart demonstrated protective efficacy of 71.3% against medically attended RSV lower respiratory tract infections (LRTI) and 71.7% against RSV LRTI leading to hospitalization. Protection against severe RSV LRTI was even stronger, reaching 93.9% (medically attended) and 90.1% (hospitalization). Crucially, through the 270-day observation period, these protective efficacies were maintained at 69.9% and 69.8% for RSV LRTI and 90.2% and 83.5% for severe RSV LRTI respectively — validating the single-dose, full-season-plus durability profile.
Market Impact & Outlook
- Global first in durability: Up to nine months of single-dose protection distinguishes Retavibart in the rapidly expanding RSV immunoprophylaxis market, potentially covering more than a typical epidemic season
- Severe disease protection: Efficacy exceeding 90% against severe RSV LRTI at both time points addresses the outcomes that drive hospital burden and parental anxiety most directly
- Massive addressable market: Virtually all infants encounter RSV in their first years of life, and China’s annual birth cohort represents one of the world’s largest RSV prevention opportunities
- Priority review validation: The NMPA’s priority pathway endorsement underscores the drug’s public health significance and accelerates time to first use
- Strategic signal: The approval cements Trinomab Biopharmaceutical’s (SHA: 688806) position in pediatric infectious disease prevention, a category increasingly prioritized by Chinese regulators and payers
Forward‑Looking Statements: This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding commercialization plans, market uptake and reimbursement outcomes are forward-looking and subject to risks and uncertainties, including pricing policy, competitive developments and real-world adoption. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.-Fineline Info & Tech